Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.25
Bid: 14.00
Ask: 14.50
Change: 0.00 (0.00%)
Spread: 0.50 (3.571%)
Open: 14.25
High: 14.25
Low: 14.25
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Strategic Partnership

27 Jul 2006 07:00

Angle PLC27 July 2006 For Immediate Release 27 July 2006 ANGLE plc ('ANGLE' or 'the Company') 20 year strategic partnership with The University of Reading ANGLE plc ('ANGLE'), the venture management and consulting company specialisingin the commercialisation of technology, is pleased to announce that it hassigned a 20 year strategic partnership with The University of Reading ('University'). Under the terms of the agreement, ANGLE has the exclusive right of first refusalto invest in all University intellectual property (IP) that is commercialised.Where ANGLE exercises this right, it will invest under a set formula obtainingan equity stake of 60% in each spin-out company for an investment of up to £0.5million. ANGLE will drive development of these ventures utilising itsproprietary Progeny(R) process. Additionally, ANGLE will receive a 15% share in all commercial returns fromUniversity IP, both licensing and spin-out, in which ANGLE does not invest. Inexchange, ANGLE will provide consultancy support to the University on IPcommercialisation. In total, ANGLE expects to invest at least £3.0 million over the first fiveyears of the agreement and expects that this will be funded from existingresources. The University has income of more than £150 million per annum and over 1,000academic staff. The most recent government Research Assessment Exercise ratedtwenty of its departments as 5 or 5*, denoting international excellence inresearch activity. This excellence is found in areas as diverse as climatephysics, fluid dynamics and food biosciences, the latter of which is ideallyplaced as the global market for functional foods grows towards an estimated $95billion per annum by 2010. In addition, the University's Instrumentation &Signal Processing Research Group and Cybernetic Intelligence Research Group bothpossess not only high international reputations but also strong histories ofproducing groundbreaking, commercial technologies. ANGLE is already workingwith the University to evaluate opportunities arising from these and otherareas. The University has a long tradition of being at the forefront of commercialactivities, as the first British university to integrate an industrial R&D groupon its campus; the first university to win the Queen's Award for ExportAchievement; the host to the UK's leading Knowledge Transfer Partnership (KTP)Centre; the provider of one of the largest credit bearing entrepreneurshipteaching programmes in the UK; and the home of InnovationWorks@Reading, afacility for creative problem solving unique in the South East. Existingspin-out companies include Whitfield Solar, a developer of low-cost solar powersolutions that has recently joined the Carbon Trust's Incubator managed byANGLE. ANGLE's Director of New Ventures, Stephen Bence, said: "The University of Reading is a top rated research University with strength indepth through its technology base. We are delighted to have the opportunity towork with the University to commercialise its intellectual property over anextended period of time and look forward to some early successes." ANGLE's Group Chief Executive, Andrew Newland, added: "We are delighted to sign The University of Reading as ANGLE's first UKstrategic partnership. Establishing long-term relationships with owners ofimpressive intellectual property represents a new phase in ANGLE's strategicdevelopment. This ground-breaking deal is the first of a number of such dealsthat we expect to be able to announce over the next 18 months." David Savage, Director of Finance and Corporate Services at The University ofReading, said: "We have been approached by a number of IP commercialisation groups interestedin investing in the University's intellectual property but ANGLE offered aunique combination of consultancy expertise in identifying opportunities andproactive management of their development. We are confident that this strategicpartnership will deliver a step change in technology transfer from TheUniversity of Reading for the benefit of the UK economy." The University's Technology Transfer Manager, Sue O'Hare, added: "ANGLE's track record of successful spin-out companies and network ofexperienced and well-connected people are impressive. We are very excited by theopportunity to work closely with them to realise the potential of theUniversity's intellectual property and to maintain and develop the University'srecord of being at the leading edge." For further information ANGLE plc +44 1483 295830Andrew Newland, Chief ExecutiveStephen Bence, Director of New Ventures The University of Reading +44 118 935 7198Sue O'Hare, Technology Transfer Manager Buchanan Communications +44 20 7466 5000Richard Darby, Suzanne Brocks, James Strong, Amy Rajendran Note to editors: About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from officesin the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com About The University of Reading The University of Reading is one of the top 20 research-intensive universitiesin the UK, with a world-wide reputation in the areas of environmentaltechnologies, agriculture, food biosciences, information and communicationstechnologies, construction management, and financial markets. The University iscommitted to achieving excellence in research, teaching and enterprise and totranslating its excellence into a major contribution to culture, economicwell-being and the quality of life. For more information, visit www.reading.ac.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
23rd Jul 20147:00 amRNSPreliminary Results
22nd Jul 20147:00 amRNSParsortix Evaluation
1st Jul 20147:00 amRNSNotification of Preliminary Results
29th Apr 20144:30 pmRNSHoldings in Company
8th Apr 20147:00 amRNSIntellectual Property Update
24th Mar 20147:00 amRNSAppointment of Scientific Adviser
17th Mar 20147:00 amRNSParsortix FDA Submission
24th Feb 20147:00 amRNSUse of Parsortix System with Liver Cancer Patients
18th Feb 20147:00 amRNSParsortix Launch at Circulate Conference in Berlin
30th Jan 20147:00 amRNSInterim Results
13th Jan 20147:00 amRNSCambridge Parsortix Laboratory
10th Jan 20147:00 amRNSNotification of Interim Results and Webcast
7th Jan 20147:00 amRNSAppointment of Scientific Adviser
17th Dec 20137:00 amRNSCE Mark Authorisation
13th Dec 20137:00 amRNSRaises £6.2m from Sale of Geomerics
31st Oct 20133:31 pmRNSResult of 2013 Annual General Meeting
9th Oct 20137:00 amRNSAnnual Report and Accounts and Notice of AGM
31st Jul 20137:00 amRNSPreliminary Results
25th Jul 20137:00 amRNSPositive Evaluation of Parsortix System
19th Jul 20137:00 amRNSNotification of Preliminary Results and Webcast
8th Jul 20137:00 amRNSParsortix Colorectal Cancer Validation
29th May 20137:00 amRNSDirector's Share Transfer
28th May 20137:00 amRNSParsortix Manufacturer Appointed
13th May 20137:00 amRNSPARSORTIX CELL HARVESTING
7th May 20137:00 amRNSParsortix Regulatory Approval Update
28th Feb 20137:00 amRNSParsortix Research Product Launch
15th Feb 201310:56 amRNSDirector's share transfer
31st Jan 20137:01 amRNSFundraising and Director's Dealings
31st Jan 20137:00 amRNSInterim Results
16th Jan 20137:00 amRNSNotification of Interim Results and Webcast
14th Jan 20137:00 amRNSParsortix Cell Recovery
7th Jan 20137:00 amRNSAppointment of NED
18th Dec 20127:00 amRNSParsortix Released to Research Partners
10th Dec 20127:00 amRNSBUSINESS UPDATE
18th Oct 20127:00 amRNSAppointment of Scientific Advisers
17th Oct 20123:45 pmRNSHolding(s) in the Company
11th Oct 20123:39 pmRNSResult of 2012 Annual General Meeting
3rd Sep 20127:00 amRNSIncreased Fundraising
1st Aug 20127:00 amRNSIncreased Fundraising
26th Jul 20127:01 amRNSFundraising
26th Jul 20127:00 amRNSPreliminary Results
24th Jul 20127:00 amRNSNotice of Preliminary Results and Conference Call
27th Jun 20127:00 amRNSOffer Unconditional for Novocellus' Partner Origio
7th Jun 20127:00 amRNSUpdate Re Novocellus' Partner ORIGIO A/S
16th May 20127:00 amRNSGeomerics Milestone Payment
30th Apr 20127:00 amRNSParsortix Design Breakthrough
26th Apr 20127:00 amRNSLaunches New Corporate Website
23rd Apr 20127:00 amRNSParsortix Update for Breast Cancer
17th Apr 20127:00 amRNSParsortix Validation for Ovarian Cancer
11th Apr 20127:00 amRNSNovocellus Embryosure® Trial Started

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.